Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 112,400 shares, a drop of 82.8% from the September 15th total of 652,500 shares. Approximately 6.4% of the company's stock are short sold. Based on an average daily volume of 806,900 shares, the short-interest ratio is presently 0.1 days.
Monopar Therapeutics Stock Up 1.8 %
Shares of NASDAQ:MNPR traded up $0.09 on Thursday, reaching $5.17. 44,151 shares of the company's stock were exchanged, compared to its average volume of 623,527. The business's 50-day moving average is $3.44 and its two-hundred day moving average is $3.49. Monopar Therapeutics has a fifty-two week low of $1.37 and a fifty-two week high of $8.65. The firm has a market capitalization of $90.39 million, a price-to-earnings ratio of -9.77 and a beta of 1.26.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Analysts predict that Monopar Therapeutics will post -1.93 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, HC Wainwright increased their target price on Monopar Therapeutics from $2.00 to $6.00 and gave the stock a "buy" rating in a report on Wednesday, August 14th.
Read Our Latest Report on MNPR
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
